A Ruffatti

Summary

Affiliation: University of Padova
Country: Italy

Publications

  1. ncbi request reprint Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature
    Amelia Ruffatti
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    Autoimmun Rev 6:196-202. 2007
  2. ncbi request reprint Plasmapheresis, intravenous immunoglobulins and bethametasone - a combined protocol to treat autoimmune congenital heart block: a prospective cohort study
    Amelia Ruffatti
    Rheumatology Unit, Department of Medicine, University of Padua, Italy
    Clin Exp Rheumatol 34:706-13. 2016
  3. ncbi request reprint Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review
    Amelia Ruffatti
    Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy
    Clin Rev Allergy Immunol . 2016
  4. doi request reprint Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study
    Amelia Ruffatti
    Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy Electronic address
    J Reprod Immunol 115:14-9. 2016
  5. doi request reprint Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block
    Amelia Ruffatti
    Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua, Italy Electronic address
    Transfus Apher Sci 53:269-78. 2015
  6. doi request reprint Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study
    Amelia Ruffatti
    Amelia Ruffatti, Reumatologia, Policlinico Universitario, Via Giustiniani, 2 35128 Padova, Italy, Tel 039 049 8212192, Fax 039 049 8212191, E mail
    Thromb Haemost 112:727-35. 2014
  7. doi request reprint A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature
    Amelia Ruffatti
    Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy
    Autoimmun Rev 12:768-73. 2013
  8. doi request reprint Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome
    A Bontadi
    Reumatologia, Policlinico Universitario, Via Giustiniani 2, Padua, Italy
    Thromb Haemost 109:901-8. 2013
  9. doi request reprint A combination therapy to treat second-degree anti-Ro/La-related congenital heart block: a strategy to avoid stable third-degree heart block?
    A Ruffatti
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Lupus 21:666-71. 2012
  10. doi request reprint Risk-based secondary prevention of obstetric antiphospholipid syndrome
    A Ruffatti
    Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy
    Lupus 21:741-3. 2012

Detail Information

Publications62

  1. ncbi request reprint Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature
    Amelia Ruffatti
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    Autoimmun Rev 6:196-202. 2007
    ..Further studies in this type of patients are certainly warranted...
  2. ncbi request reprint Plasmapheresis, intravenous immunoglobulins and bethametasone - a combined protocol to treat autoimmune congenital heart block: a prospective cohort study
    Amelia Ruffatti
    Rheumatology Unit, Department of Medicine, University of Padua, Italy
    Clin Exp Rheumatol 34:706-13. 2016
    ..We set out to carry out a prospective cohort study to evaluate the benefits, limits, and safety of a combined therapy protocol to treat antibody-related CHB...
  3. ncbi request reprint Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review
    Amelia Ruffatti
    Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy
    Clin Rev Allergy Immunol . 2016
    ..This is a comprehensive review on this topic and an invitation to participate in a multicentre study in order to identify the best additional treatments to be used in this subset of antiphospholipid syndrome patients...
  4. doi request reprint Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study
    Amelia Ruffatti
    Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy Electronic address
    J Reprod Immunol 115:14-9. 2016
    ..No treatment side effects were registered. Given the high live birth rate and the safety associated to it, the study protocol described here could be taken into consideration by medical teams treating high-risk APS pregnant patients. ..
  5. doi request reprint Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block
    Amelia Ruffatti
    Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua, Italy Electronic address
    Transfus Apher Sci 53:269-78. 2015
    ..If these results are confirmed by large-scale studies, the apheretic procedures could lead to improved outcomes in the treatment of these devastating diseases. ..
  6. doi request reprint Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study
    Amelia Ruffatti
    Amelia Ruffatti, Reumatologia, Policlinico Universitario, Via Giustiniani, 2 35128 Padova, Italy, Tel 039 049 8212192, Fax 039 049 8212191, E mail
    Thromb Haemost 112:727-35. 2014
    ....
  7. doi request reprint A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature
    Amelia Ruffatti
    Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy
    Autoimmun Rev 12:768-73. 2013
    ..The aim of this report was to evaluate the efficacy and safety of a combined treatment protocol used to treat 2nd and 3rd degree anti-Ro/La-related congenital atrioventricular block (CAVB)...
  8. doi request reprint Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome
    A Bontadi
    Reumatologia, Policlinico Universitario, Via Giustiniani 2, Padua, Italy
    Thromb Haemost 109:901-8. 2013
    ..In addition, sP-sel and von Willebrand factor activity were significantly higher during catastrophic than in quiescent phase...
  9. doi request reprint A combination therapy to treat second-degree anti-Ro/La-related congenital heart block: a strategy to avoid stable third-degree heart block?
    A Ruffatti
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Lupus 21:666-71. 2012
    ..Moreover, there was no recurrence of CHB when therapy was suspended, as confirmed by a 29 month and an eight month follow-up, respectively...
  10. doi request reprint Risk-based secondary prevention of obstetric antiphospholipid syndrome
    A Ruffatti
    Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy
    Lupus 21:741-3. 2012
    ....
  11. doi request reprint Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome
    A Ruffatti
    University of Padua, Padua, Italy
    Arthritis Care Res (Hoboken) 62:302-7. 2010
    ..To evaluate the relationship between the antiphospholipid profile and clinical characteristics of pregnant women with antiphospholipid syndrome (APS) and neonatal outcome...
  12. doi request reprint Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study
    Amelia Ruffatti
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Ann Rheum Dis 70:1083-6. 2011
    ..To assess risk factors for a first thrombotic event in confirmed antiphospholipid (aPL) antibody carriers and to evaluate the efficacy of prophylactic treatments...
  13. ncbi request reprint Adjusted prophylactic doses of nadroparin plus low dose aspirin therapy in obstetric antiphospholipid syndrome. A prospective cohort management study
    A Ruffatti
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Clin Exp Rheumatol 29:551-4. 2011
    ..The efficacy and safety of adjusted single daily doses of LMWH (nadroparin) combined with LDA have thus been evaluated in 33 consecutive pregnancies in women with diagnosed obstetric APS...
  14. doi request reprint Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study
    Amelia Ruffatti
    Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Padua, Padua, Italy
    Rheumatology (Oxford) 50:1684-9. 2011
    ..To identify the risk factors associated with pregnancy failure in patients with APS treated with conventional therapy...
  15. doi request reprint Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study
    A Ruffatti
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Ann Rheum Dis 68:397-9. 2009
    ..To asses risk factors for a first thrombotic event in antiphospholipid antibody (aPL) positive carriers and evaluate the efficacy of prophylactic treatments...
  16. doi request reprint Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification
    A Ruffatti
    Rheumatology Unit, University of Padua, Padua, Padova, Italy
    J Thromb Haemost 6:1693-6. 2008
    ....
  17. ncbi request reprint Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis
    Amelia Ruffatti
    Department of Medical and Surgical Sciences, University of Padova, Italy
    J Rheumatol 29:918-23. 2002
    ..We evaluated the prevalence and clinical significance of proteinase 3 (PR3-) and myeloperoxidase (MPO-) antineutrophil cytoplasmic antibodies (ANCA) in 115 patients with systemic sclerosis (SSc, scleroderma)...
  18. ncbi request reprint Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study
    A Ruffatti
    University of Padova, Padova, Italy
    Lupus 14:120-8. 2005
    ....
  19. ncbi request reprint Sensitivity and specificity for primary Sjögren's syndrome of IgA and IgG anti-alpha-fodrin antibodies detected by ELISA
    Amelia Ruffatti
    Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
    J Rheumatol 31:504-7. 2004
    ..To investigate the sensitivity and specificity of anti-alpha-fodrin antibodies in patients with primary Sjögren's syndrome (pSS)...
  20. doi request reprint Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile
    V Pengo
    Clinical Cardiology, Thrombosis Center, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    J Thromb Haemost 11:1527-31. 2013
    ..Consequently, classification of patient risk and adequacy of treatment may be deferred by 3 months...
  21. doi request reprint Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome
    A Hoxha
    Rheumatology Unit, Department of Medicine, University of Padua, Italy
    Lupus 21:787-9. 2012
    ..6-7.9] and OR 4.1 [95% CI 1.4-11.7], respectively) and IgM aPS/PT was an independent risk factor for arterial thrombosis (OR 2.7 [95% CI 1.1-6.7]). In conclusion, these findings indicate that aPS/PT are clinically relevant in PAPS...
  22. doi request reprint Antiphospholipid syndrome: critical analysis of the diagnostic path
    V Pengo
    Clinical Cardiology, Thrombosis Centre, University of Padova, School of Medicine, Padova, Italy
    Lupus 19:428-31. 2010
    ..Conversely, all three positive tests identify a single class of abeta2GPI antibodies, thus identifying high-risk patients with APS...
  23. doi request reprint Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Thrombosis Center, University Hospital, Padova, Italy
    J Thromb Haemost 8:237-42. 2010
    ..The characteristics and the clinical course of antiphospholipid syndrome (APS) in high-risk patients that are positive for all three recommended tests that detect the presence of antiphospholipid (aPL) antibodies have not been described...
  24. doi request reprint Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy
    A Ruffatti
    Department of Clinical and Experimental Medicine, University of Padua, Italy
    Thromb Res 123:482-7. 2009
    ..A relationship between antibody profile and pregnancy outcome in patients with a previous diagnosis of primary antiphospholipid syndrome (APS) has not been clearly documented...
  25. doi request reprint APS - Diagnostics and challenges for the future
    V Pengo
    Department of Cardiac, Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, Padova, Italy Department of Medicine, Division of Rheumatology, University of Padova Medical School, Padova, Italy Electronic address
    Autoimmun Rev 15:1031-1033. 2016
    ..We do not yet know what is the physiological function of β2GP1 and the pathophysiology of thrombosis and pregnancy loss in these patients. Moreover, treatment is poorly defined especially in the case of feared catastrophic APS...
  26. doi request reprint Correct laboratory approach to APS diagnosis and monitoring
    V Pengo
    Department of Cardiac, Thoracic and Vascular Sciences, University of Padova Medical School, Padova, Italy
    Autoimmun Rev 12:832-4. 2013
    ..Thus, very different risk categories exist among patients with APS as well as among carriers of aPL. Clinical studies and interventional trials should first take these high risk subjects into consideration...
  27. doi request reprint The clinical significance of autoantibodies directed against prothrombin in primary antiphospholipid syndrome
    A Hoxha
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Clin Chim Acta 413:911-3. 2012
    ..To evaluate the clinical significance of IgG/IgM antibodies directed against prothrombin (PT) in a homogeneous cohort of patients with primary APS (PAPS)...
  28. doi request reprint Laboratory testing for antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Department of Cardiac, Thoracic, and Vascular Sciences and Division of Rheumatology, University of Padova, Padova, Italy
    Int J Lab Hematol 38:27-31. 2016
    ..Interpretation of results is an important discussed issue that implies a close liaison between clinical pathologists and clinicians. Finally, a personal definition of APS according to aPL antibody profile closes the manuscript. ..
  29. doi request reprint Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles
    V Pengo
    Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy Electronic address
    Thromb Res 136:161-3. 2015
    ....
  30. doi request reprint Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome
    A Banzato
    Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Italy
    Lupus 21:784-6. 2012
    ....
  31. doi request reprint Secondary prevention in thrombotic antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    Lupus 21:734-5. 2012
    ..The duration of treatment is usually indefinite because of a substantial risk of recurrence...
  32. doi request reprint The antiphospholipid syndrome and infections in a child with trisomy 21
    A Hoxha
    Rheumatology Unit, University of Padua, Padua, Italy
    Autoimmun Rev 8:121-3. 2008
    ..It can be hypothesized that some infections not only "trigger" antiphospholipid antibody production, but--in genetically predisposed subjects--can induce the clinical manifestations of the antiphospholipid syndrome...
  33. doi request reprint Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk
    V Pengo
    Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    J Thromb Haemost 13:782-7. 2015
    ..Determination of lupus anticoagulant (LA), anticardiolipin (aCL) and β2-Glycoprotein 1 (aβ2GP1) antibodies is mandatory to classify patients with antiphospholipid syndrome (APS) into risk categories...
  34. ncbi request reprint Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins
    P Rampazzo
    Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova, Italy
    Thromb Haemost 85:57-62. 2001
    ..In conclusion, some patients with APS harbor circulating antibodies to other CL-binding proteins which might be useful to further characterize these patients...
  35. doi request reprint Interpretation of laboratory data and need for reference laboratories
    V Pengo
    Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Italy
    Lupus 21:732-3. 2012
    ..Monoclonal antibodies against Domain I with Lupus Anticoagulant activity might be candidate material for standardization of antiphospholipid assays. Much work remains to be done in this field...
  36. doi request reprint Antibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS)
    A Banzato
    Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Via Giustiniani, 2 35128 Padova, Italy
    Thromb Res 128:583-6. 2011
    ..The relation between anti-DmI antibodies and patients' risk categories is unknown...
  37. ncbi request reprint Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity
    Amelia Ruffatti
    Department of Clinical and Experimental Medicine, Division of Rheumatology, University of Padua, Italy
    Thromb Haemost 96:337-41. 2006
    ..Triple positivity and/or a history of thromboembolism predict new TE events and new unsuccessful pregnancies...
  38. doi request reprint Are biological drugs safe in pregnancy?
    A Calligaro
    Rheumatology Unit, Department of Medicine DIMED, University of Padua
    Reumatismo 66:304-17. 2015
    ..Pregnancy data for rituximab, abatacept, anakinra, tocilizumab and belimumab are limited and their use in pregnancy cannot currently be recommended...
  39. ncbi request reprint [Clinical significance of fluoroscopic patterns specific for the mitotic spindle in patients with rheumatic diseases]
    P Grypiotis
    Cattedra e Divisione di Reumatologia, Universita degli Studi di Padova
    Reumatismo 54:232-7. 2002
    ..To determine the clinical significance of anti-NuMA and anti-HsEg5 antibodies in a group of patients affected with rheumatic diseases...
  40. doi request reprint Antibodies to oxidized LDL/beta2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism
    V Pengo
    Department of Cardio Thoracic and Vascular Sciences, Clinical Cardiology, Italy
    Thromb Res 122:556-9. 2008
    ..Data from this study do not support the hypothesis that IgG anti-oxLDL/beta2GPI are specifically associated to arterial TE in Category I APS patients...
  41. ncbi request reprint [Isolated congenital heart block in undifferentiated connective tissue disease and in primary Sjögren's syndrome: a clinical study of 81 pregnancies in 41 patients]
    C Grava
    Cattedra e Unità Operativa di Reumatologia, Universita degli Studi di Padova
    Reumatismo 57:180-6. 2005
    ..To study the incidence and the features of congenital heart block (CHB) in patients with undifferentiated connective tissue disease (UCTD) and primary Sjögren's syndrome (pSS)...
  42. doi request reprint Systemic sclerosis and aortic valve stenosis: therapeutic implications in two cases of aortic valve replacement
    Sandro Sponga
    Department of Cardiac Surgery, Italy
    J Cardiovasc Med (Hagerstown) 10:560-2. 2009
    ..We describe herein two cases of valve replacement because of aortic stenosis...
  43. doi request reprint Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA)
    V Pengo
    Clinical Cardiology, Thrombosis Centre, University Hospital, Padova
    Thromb Res 126:150-3. 2010
    ..The aim of this study was to determine their presence and association with thromboembolic events in a large series of patients with confirmed LA...
  44. ncbi request reprint Pregnancy, cytokines, and disease activity in systemic lupus erythematosus
    Andrea Doria
    University of Padova, Padova, Italy
    Arthritis Rheum 51:989-95. 2004
    ..To evaluate levels of selected cytokines and soluble receptors involved in the humoral immune response during pregnancy in systemic lupus erythematosus (SLE) patients...
  45. ncbi request reprint Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome
    Panagiotis Grypiotis
    Rheumatology Unit, University of Padova, Padova, Italy
    J Clin Lab Anal 20:15-8. 2006
    ..Moreover, the highest sensitivity was reached with a combination of SCT and dRVVT. The method's association with total thrombotic events and venous thrombosis was in fact significant...
  46. ncbi request reprint The diagnosis of the antiphospholipid syndrome
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Center, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy
    Pathophysiol Haemost Thromb 35:175-80. 2006
    ..In the near future, coagulation tests discriminating between a beta2-GPI and anti-prothrombin LAC may be useful in identifying high risk patients...
  47. ncbi request reprint An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay results
    Anna Cavazzana
    Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Padua, Padua, Italy
    Ann N Y Acad Sci 1109:484-92. 2007
    ..As variations in abeta(2)GPI ELISA conditions determine significant differences in the results, selecting the appropriate test variables is an important step toward abeta(2)GPI assay standardization...
  48. doi request reprint Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome
    Maria Bortolati
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Ther Apher Dial 13:157-60. 2009
    ..Nevertheless, as a whole these data suggest better disease control using the immunoadsorption technique as compared to plasma exchange, despite their apparently similar anti-beta2 glycoprotein I antibody removal capabilities...
  49. doi request reprint Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature
    Maria Bortolati
    Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Autoimmun Rev 8:297-301. 2009
    ..Our results indicate that, when initiated promptly and albumin solution is used as the replacement fluid, TPE can be considered an effective, safe treatment for CAPS...
  50. ncbi request reprint Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study
    Anna Ghirardello
    Division of Rheumatology, University of Padova, Italy
    Clin Exp Rheumatol 29:50-6. 2011
    ..An Italian multicentre study was promoted in order to assess the accuracy of four anti-double-stranded DNA (dsDNA) antibody assays for SLE diagnosis and monitoring...
  51. ncbi request reprint [Digital ulcers in a cohort of 333 scleroderma patients]
    F Tiso
    Cattedra e U O C di Reumatologia, Dipartimento di Medicina Clinica e Sperimentale, Policlinico Universitario, Padova, Italia
    Reumatismo 59:215-20. 2007
    ..Recently the efficacy of bosentan, an oral receptor antagonist of endothelin, has been demonstrated, thus opening new perspectives in the treatment of DU in systemic sclerosis...
  52. ncbi request reprint Biological and clinical relevance of anti-prothrombin antibodies
    Anna Ghirardello
    Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Ann N Y Acad Sci 1109:503-10. 2007
    ....
  53. pmc Identification of discrete epitopes of Ro52p200 and association with fetal cardiac conduction system manifestations in a rodent model
    A Hoxha
    Department of Medicine, Rheumatology Unit, University of Padua, Padua, Italy
    Clin Exp Immunol 186:284-291. 2016
    ..Our findings support the hypothesis that several fine antibody specificities and cross-targets may exist and contribute to CHB development in anti-Ro52 antibody-positive pregnancies...
  54. ncbi request reprint Unstabilized DNA breaks in lymphocytes of patients with different subsets of systemic sclerosis
    Franca Majone
    Department of Biology, University of Padua, Padua, Italy
    Ann N Y Acad Sci 1108:240-8. 2007
    ..18%). Our results indicate that there is a clastogenic effect on DNA and an interference in the protective cellular mechanisms normally stabilizing DNA breaks only in some subsets of SSc patients...
  55. ncbi request reprint Images in cardiovascular medicine. Calcification of the atrioventricular node in a fetus affected by congenital complete heart block
    Annalisa Angelini
    Department of Pathology, University of Padua Medical School, Padua, Italy
    Circulation 105:1254-5. 2002
  56. doi request reprint Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis
    Franca Majone
    Department of Biology, University of Padua, Padua, Italy
    Rheumatol Int 29:891-5. 2009
    ..001) groups. Moreover, apoptosis was distributed homogenously in ACA and ATA positive subjects, but not in the ARA patients. Our results show that there is an increase in apoptosis in the lymphocytes of ARA positive SSc patients...
  57. ncbi request reprint Unstabilized DNA breaks in lymphocytes of patients with systemic sclerosis
    Franca Majone
    Department of Biology, University of Padova, Italy
    Eur J Dermatol 16:258-61. 2006
    ..08%, p < 0.001). Our results indicate that in SSc patients there is an interference in the protective cellular mechanisms, normally stabilizing DNA breaks...
  58. ncbi request reprint Antiphospholipid syndrome and right atrial mass
    Cristina Basso
    Institute of Pathological Anatomy, University of Padua Medical School, Padua, Italy
    J Thorac Cardiovasc Surg 130:1462-3. 2005
  59. ncbi request reprint Autoantibodies to bactericidal/permeability-increasing protein and cathepsin G in systemic sclerosis
    Panagiotis Grypiotis
    J Rheumatol 31:1468-9. 2004
  60. ncbi request reprint Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report
    Antonio Furlan
    Joint Bone Spine 75:366-7. 2008
  61. ncbi request reprint Plasma exchange in a patient with primary antiphospholipid syndrome undergoing kidney transplantation
    Amelia Ruffatti
    Transpl Int 20:475-7. 2007
  62. ncbi request reprint Features associated with epilepsy in the antiphospholipid syndrome
    Yehuda Shoenfeld
    Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel
    J Rheumatol 31:1344-8. 2004
    ....